Esophageal Cancer Action Network’s Post

In our recent study, we explored how distinct invasion modes in KRAS-driven lung cancer contribute to tumor progression and therapy responses. We identified that loss of LKB1 in lung adenocarcinoma leads to increased BMP6 signaling, promoting growth through the iron-regulatory hormone hepcidin. Our findings suggest that targeting the ALK2/BMP6 pathway could be a promising therapeutic strategy for patients with LKB1-mutant tumors. This work highlights a novel approach to addressing tumor invasion and growth in KRAS-driven lung cancer.

Lung Cancer Foundation of America believes in the power of science and community, which si why we are such good friends. Here, lung cancer patients know they are not alone and can access valuable information. This quote says it all: preserving tumor samples for DNA sequencing and other studies can lead to a deeper understanding of their cancer, more personalized treatment options, and potentially better outcomes. Ongoing research is important. And every detail can contribute to advancing knowledge and care for lung cancer patients. Join today to learn more: https://lnkd.in/gY2UU9gx

In a textbook case of semantic drift, the breast cancer gene "BRCA" needs to be better understood. It stands for "BReast CAncer," but these genes are about much more than just breast cancer. BRCA1 and BRCA2 mutations also significantly increase the risk of ovarian, pancreatic, prostate cancer, and even others. Join our webinar and we'll discuss what BRCA really means for cancer risk, treatment, and family planning. It's time to understand the full story behind BRCA mutations. https://lnkd.in/grqycDZj Hope to see you there and help spread awareness beyond just the name.

Targeted therapy plays an important role for patients with early and advanced-stage non-small cell lung cancer carrying specific genetic alterations. In this video, Dr. Maisam Makarem and Dr. Pasi Jänne of Dana-Farber Cancer Institute break down the latest advances in targeted therapy for lung cancer. Learn more about the latest advances in targeted therapy for lung cancer: https://lnkd.in/eH9wd_aN OncoAlert American Cancer Society #lungcancer #lungcancerresearch #targetedtherapy

Runx3 Paradox: Opening The Pandora Box Over the past few decades, the function of the Runt-related transcription factors (RUNX) family in cancer has been extensively studied, and has been reported as bona fide tumor suppressors. Howevr this narrative is challanged extensivly, since RUNX family members (Runx1, 2, and 3) are now being considered as promising targets for cancer diagnosis and treatment with a potential of Runx3 being an epigenetic modulator in cancer. My recent observations supported the notion that Runx3 act as a proto-oncogene rather than a tumor suppressor. This was evident with its null expression in normal tissue that increases and become upregulated with advanced cancer stages. (see: https://lnkd.in/g9RzdqHS). Earlier reports also requtested the examination of Runx3 classification as tumor suppresor that was considered as a false paradigm: 1. https://lnkd.in/gdFtaBYD. 2. https://lnkd.in/g9FJQFCQ

Testosterone's link to prostate cancer has been misunderstood for years. In the 1940s, research made it seem like testosterone fueled cancer growth, leading people to think low levels were safer. However, modern studies show no solid proof that high testosterone increases prostate cancer risk. In fact, the saturation model suggests once the prostate has enough testosterone, extra amounts don't affect cancer growth. Surprisingly, low testosterone might actually be tied to more aggressive forms of prostate cancer. It's time to rethink the connection between testosterone and prostate cancer. To learn more about this topic check out: https://lnkd.in/e4k7BNNJ #ProstateCancerMyths #TestosteroneResearch #LowTestosteroneRisks

Capturing T-cells fighting cancer ⚡️ on video‼️ A sensor in the cancer cell illuminates upon impact, providing real-time data to help improve treatments The cancer cell contains a sensor that lights up when it is attacked by the T-cell. This remarkable video clip (credit goes to Jeroen Slaats) vividly illustrates the process that occurs following immunotherapy and depicts a Cytotoxic T-Lymphocyte (CTL) attacking a tumor cell. Cell therapy, including the anti-tumor specific cells known as CAR-T cells, has transitioned from being a futuristic concept to a current reality in cancer treatment. Credit to Jeroen Slaats and biotech.symposium https://lnkd.in/e7a-eS27

The research led by the late John Herr and continued by Dr. Craig Slingluff Jr. at the University of Virginia focuses on the SAS1B protein, which could revolutionise treatment for tough-to-treat cancers like breast cancer, lung cancer, and melanoma. Found in cancer cells but not normal cells, SAS1B presents a promising target for selective, antibody-based immunotherapies. This approach could significantly improve treatment outcomes by specifically targeting cancer cells and sparing healthy tissue. While promising, more research and clinical trials are needed to fully realise the potential of this discovery. This work illustrates the potential for significant advances in cancer treatment through immunotherapy. #lungscreen #science #research

“By sequencing the molecular changes in the cells, the group identified the DUSP6 protein, whose expression closely followed the development of therapy resistance. The leading researcher Majid Momeny was also able to show that when the activity of the DUSP6 protein was blocked during cancer treatment, breast cancer cells lost their ability to grow. Blocking the protein also made the previously treatment-resistant cancer cells more sensitive to HER2 inhibitors. Another important finding was that by inhibiting DUSP6, it was possible to slow the growth of breast cancer metastases in the brain in mouse models. “ #breastcancer #cancerresearch #recurrance #metastasis #adjuvantthrerapy #cancertreatment

Weill Cornell Medicine has received a $1.4 million, four-year grant to explore a new therapeutic approach for clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The grant is one of 10 Idea Awards the U.S. Department of Defense funded this year to support innovative, high-risk, high-reward science that could lead to a shift in cancer care. The funding will enable lead researchers Dr. Lorraine Gudas and Dr. David Nanus of Weill Cornell Medicine to study a cellular reprogramming strategy that may improve patients' responses to checkpoint inhibitors, a form of immunotherapy. Full story: https://bit.ly/3D8AfK6